PUBLISHER: Acute Market Reports | PRODUCT CODE: 1293832
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1293832
Viral Vectors and Plasmid DNA Manufacturing Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
The viral vectors and plasmid DNA manufacturing market is expected to grow at a CAGR of 22.5% during the forecast period of 2023 to 2031, driven by the increasing demand for advanced gene therapies, vaccines, and cell-based therapies. The market revenue is expected to witness substantial growth in the coming years, with a promising compound annual growth rate (CAGR).Viral vectors and plasmid DNA are essential components in the development and production of gene therapies and vaccines. Viral vectors, such as adenoviruses, lentiviruses, and adeno-associated viruses (AAVs), are used to deliver genetic material into target cells, enabling the modification or correction of specific genes associated with various diseases. Plasmid DNA, on the other hand, serves as a vehicle for carrying therapeutic genes, providing the necessary instructions for protein synthesis within cells.The market for viral vectors and plasmid DNA manufacturing is driven by advancements in biotechnology and genetic engineering, which have revolutionized the field of medicine. Gene therapies have shown tremendous potential in treating a range of genetic disorders, rare diseases, and certain types of cancer. Additionally, the development of vaccines targeting infectious diseases and immunotherapies for cancer has further propelled the demand for viral vectors and plasmid DNA manufacturing.The COVID-19 pandemic has further accelerated the growth of this market, with a surge in research and development activities to develop vaccines and treatments. Several pharmaceutical companies and research organizations have focused their efforts on leveraging viral vectors and plasmid DNA to develop COVID-19 vaccines and therapeutics. This unprecedented global health crisis has highlighted the importance of viral vectors and plasmid DNA manufacturing capabilities in addressing emerging infectious diseases and public health challenges.
Growing Demand for Gene Therapies
The viral vectors and plasmid DNA manufacturing market is driven by the growing demand for gene therapies. Gene therapy offers a promising approach to treat a wide range of genetic disorders and inherited diseases by introducing functional genes into patients' cells. The increasing prevalence of genetic diseases, such as muscular dystrophy, cystic fibrosis, and hemophilia, has fuelled the demand for gene therapies. According to a study published in the Journal of the American Medical Association (JAMA), gene therapy has shown significant therapeutic benefits in clinical trials for various genetic disorders. The success of gene therapies in treating diseases that were previously untreatable or had limited treatment options has generated a strong market demand for viral vectors and plasmid DNA used in their manufacturing.
Advancements in Viral Vector Technology
Advancements in viral vector technology play a crucial role in driving the growth of the viral vectors and plasmid DNA manufacturing market. Researchers and biopharmaceutical companies are constantly working on improving the efficiency, safety, and specificity of viral vectors used in gene therapies and vaccines. For example, the development of new generation adeno-associated viruses (AAVs) with enhanced transduction capabilities and reduced immunogenicity has contributed to the success of several gene therapy trials. A study published in the journal Molecular Therapy demonstrated the potential of novel AAV variants in achieving efficient gene delivery. These advancements in viral vector technology have not only improved the efficacy of gene therapies but also expanded their application in various therapeutic areas, further driving the demand for viral vectors and plasmid DNA manufacturing.
Increasing Investments in Biotechnology Research and Development
The viral vectors and plasmid DNA manufacturing market is propelled by increasing investments in biotechnology research and development. Governments, pharmaceutical companies, and research institutions are allocating significant funds for the development of innovative therapies, including gene therapies and vaccines. For instance, the National Institutes of Health (NIH) in the United States has invested substantial resources in supporting gene therapy research and clinical trials. The European Union has also committed significant funding through its Horizon 2020 program for advancing biotechnology and gene therapy initiatives. These investments in research and development activities fuel the discovery of novel viral vectors and plasmid DNA manufacturing technologies, leading to the commercialization of advanced therapies. The growing financial support and focus on biotechnology research and development are expected to drive the viral vectors and plasmid DNA manufacturing market in the coming years.
Regulatory Challenges and Safety Concerns
The viral vectors and plasmid DNA manufacturing market faces regulatory challenges and safety concerns that serve as a restraint to its growth. The development and commercialization of gene therapies and vaccines involve stringent regulatory processes and safety assessments to ensure the efficacy and safety of these products. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), impose strict guidelines and requirements for the manufacturing, quality control, and clinical testing of viral vectors and plasmid DNA. Compliance with these regulations can be time-consuming and expensive for manufacturers, leading to delays in product approvals and market entry. Additionally, concerns about the potential risks associated with gene therapies, such as immune responses, off-target effects, and long-term safety profiles, pose challenges to the widespread adoption of these therapies. Reports of adverse events and safety issues in clinical trials can impact the perception and acceptance of gene therapies, affecting the demand for viral vectors and plasmid DNA manufacturing. For example, the safety concerns surrounding a gene therapy trial for the treatment of X-linked severe combined immunodeficiency (X-SCID) led to a temporary halt in the trial. These regulatory challenges and safety concerns pose a restraint to the viral vectors and plasmid DNA manufacturing market, necessitating rigorous compliance with regulations and continued research to ensure the safety and efficacy of gene therapies and vaccines.
Adenovirus Vectors Dominates the Market by Vector Type
The viral vectors and plasmid DNA manufacturing market can be segmented based on vector types, including adenovirus, retrovirus, adeno-associated virus (AAV), lentivirus, plasmids, and others. Among these, AAV is expected to witness the highest CAGR during the forecast period of 2023 to 2031. AAV vectors have gained significant attention in gene therapy applications due to their ability to efficiently deliver therapeutic genes to target cells with low immunogenicity and long-term gene expression. The use of AAV vectors in approved gene therapies, such as Luxturna and Zolgensma, has showcased their potential in treating inherited genetic disorders. As a result, the demand for AAV vectors is increasing, driving the growth of the market in terms of CAGR. In terms of revenue, adenovirus vectors held the highest share in 2022 in the viral vectors and plasmid DNA manufacturing market. Adenovirus vectors are widely used in gene therapy research and clinical trials due to their high transduction efficiency and ability to accommodate large DNA inserts. They have demonstrated success in several gene therapy applications, particularly in cancer immunotherapies and vaccine development. Moreover, the robust manufacturing processes and well-established protocols for adenovirus vectors contribute to their dominant revenue position in the market. Retrovirus vectors, including lentivirus, also hold a significant revenue share, primarily driven by their use in CAR-T cell therapies and gene-modified cell therapies. Plasmids, which serve as essential tools in gene cloning and recombinant DNA technology, contribute to the market's revenue but have a comparatively lower growth rate. Other vector types, such as herpes simplex virus (HSV) vectors and vaccinia virus vectors, hold a smaller revenue share in the market. In summary, while adenovirus vectors generate the highest revenue, AAV vectors are expected to witness the highest CAGR, driven by their promising applications in gene therapies.
North America Leads the Revenues While APAC Leads the Growth
North America held a significant share in terms of revenue in the viral vectors and plasmid DNA manufacturing market in 2022. The region has a well-established biopharmaceutical industry, robust research infrastructure, and favorable regulatory frameworks that facilitate the development and commercialization of gene therapies and vaccines. Moreover, increasing investments in research and development activities, particularly in the United States, contribute to the market's revenue growth. Europe is also a prominent region in the viral vectors and plasmid DNA manufacturing market, with a significant revenue contribution. The presence of leading biopharmaceutical companies, advancements in biotechnology research, and strong government support drive the market's growth in this region. In terms of the highest CAGR during the forecast period of 2023 to 2031, Asia Pacific is expected to top the ranl. The region has witnessed rapid growth in the biotechnology sector, driven by factors such as increasing investments in research and development, rising healthcare expenditure, and a growing focus on personalized medicine. Countries like China, Japan, and India are emerging as key players in the viral vectors and plasmid DNA manufacturing market, leveraging their scientific expertise and expanding biopharmaceutical capabilities. Latin America and the Middle East and Africa regions are also witnessing steady growth in the market, driven by the increasing focus on improving healthcare infrastructure and the adoption of advanced medical technologies.
Market Competition to Intensify During the Forecast Period
The viral vectors and plasmid DNA manufacturing market is highly competitive, with several key players actively participating in the development and production of viral vectors and plasmid DNA for gene therapies and vaccines. These companies are focusing on strategic initiatives to strengthen their market presence and gain a competitive edge.One of the top players in the market is Lonza Group, a global contract development and manufacturing organization (CDMO). Lonza offers a wide range of services, including viral vector manufacturing, plasmid DNA production, and process development.Key strategies adopted by top players and others in the market include investing in research and development activities to enhance manufacturing processes, expanding production capacity to meet the growing demand, and establishing strategic partnerships and collaborations to access novel technologies and broaden their market reach. These companies are also focusing on ensuring regulatory compliance, quality assurance, and adherence to good manufacturing practices to meet the stringent requirements of the gene therapy and vaccine industry. Moreover, competition in the viral vectors and plasmid DNA manufacturing market is further intensified by emerging players and start-ups that are entering the market with innovative technologies and platforms. These players are leveraging advancements in biotechnology and genetic engineering to develop novel viral vectors and plasmid DNA manufacturing approaches.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofViral Vectors and Plasmid DNA Manufacturing market are as follows:
- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Viral Vectors and Plasmid DNA Manufacturing market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Vector Type
- Adenovirus
- Retrovirus
- Adeno-Associated Virus (AAV)
- Lentivirus
- Plasmids
- Others
Workflow
- Upstream Manufacturing
- Vector Amplification & Expansion
- Vector Recovery/Harvesting
- Downstream Manufacturing
- Purification
- Fill Finish
Application
- Antisense & RNAi Therapy
- Gene Therapy
- Cell Therapy
- Vaccinology
- Research Applications
End-use
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Disease
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Region Segment (2021-2031; US$ Million)
- North America
- U.S.
- Canada
- Rest of North America
- UK and European Union
- UK
- Germany
- Spain
- Italy
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- Africa
- Rest of Middle East and Africa
Key questions answered in this report:
- What are the key micro and macro environmental factors that are impacting the growth of Viral Vectors and Plasmid DNA Manufacturing market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Viral Vectors and Plasmid DNA Manufacturing market?
- Which is the largest regional market for Viral Vectors and Plasmid DNA Manufacturing market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Viral Vectors and Plasmid DNA Manufacturing market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Viral Vectors and Plasmid DNA Manufacturing market worldwide?
Table of Contents
1. Preface
- 1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted
2. Executive Summary
- 2.1. Market Snapshot: Global Viral Vectors and Plasmid DNA Manufacturing Market
- 2.2. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 (US$ Million)
- 2.3. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 (US$ Million)
- 2.4. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 (US$ Million)
- 2.5. Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 (US$ Million)
- 2.6. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 (US$ Million)
- 2.7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022 (US$ Million)
- 2.8. Attractive Investment Proposition by Geography, 2022
3. Viral Vectors and Plasmid DNA Manufacturing Market: Competitive Analysis
- 3.1. Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Vendors
- 3.2. Strategies Adopted by Viral Vectors and Plasmid DNA Manufacturing Market Vendors
- 3.3. Key Industry Strategies
- 3.4. Tier Analysis 2022 Versus 2031
4. Viral Vectors and Plasmid DNA Manufacturing Market: Macro Analysis & Market Dynamics
- 4.1. Introduction
- 4.2. Global Viral Vectors and Plasmid DNA Manufacturing Market Value, 2021 - 2031, (US$ Million)
- 4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
- 4.4. Impact Analysis of Drivers and Restraints
- 4.5. See-Saw Analysis
5. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 5.1. Market Overview
- 5.2. Growth & Revenue Analysis: 2022 Versus 2031
- 5.3. Market Segmentation
- 5.3.1. Adenovirus
- 5.3.2. Retrovirus
- 5.3.3. Adeno-Associated Virus (AAV)
- 5.3.4. Lentivirus
- 5.3.5. Plasmids
- 5.3.6. Others
6. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 6.1. Market Overview
- 6.2. Growth & Revenue Analysis: 2022 Versus 2031
- 6.3. Market Segmentation
- 6.3.1. Upstream Manufacturing
- 6.3.1.1. Vector Amplification & Expansion
- 6.3.1.2. Vector Recovery/Harvesting
- 6.3.2. Downstream Manufacturing
- 6.3.2.1. Purification
- 6.3.2.2. Fill Finish
- 6.3.1. Upstream Manufacturing
7. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 7.1. Market Overview
- 7.2. Growth & Revenue Analysis: 2022 Versus 2031
- 7.3. Market Segmentation
- 7.3.1. Antisense & RNAi Therapy
- 7.3.2. Gene Therapy
- 7.3.3. Cell Therapy
- 7.3.4. Vaccinology
- 7.3.5. Research Applications
8. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 8.1. Market Overview
- 8.2. Growth & Revenue Analysis: 2022 Versus 2031
- 8.3. Market Segmentation
- 8.3.1. Pharmaceutical and Biopharmaceutical Companies
- 8.3.2. Research Institutes
9. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 9.1. Market Overview
- 9.2. Growth & Revenue Analysis: 2022 Versus 2031
- 9.3. Market Segmentation
- 9.3.1. Cancer
- 9.3.2. Genetic Disorders
- 9.3.3. Infectious Diseases
- 9.3.4. Others
10. North America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)
- 10.1. Market Overview
- 10.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 10.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 10.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 10.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 10.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 10.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
- 10.7.1.North America
- 10.7.1.1. U.S.
- 10.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 10.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 10.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 10.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 10.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 10.7.1.2. Canada
- 10.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 10.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 10.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 10.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 10.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 10.7.1.3. Rest of North America
- 10.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 10.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 10.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 10.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 10.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 10.7.1.1. U.S.
- 10.7.1.North America
11. UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)
- 11.1. Market Overview
- 11.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
- 11.7.1.UK and European Union
- 11.7.1.1. UK
- 11.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.2. Germany
- 11.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.3. Spain
- 11.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.4. Italy
- 11.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.5. France
- 11.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.6. Rest of Europe
- 11.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 11.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 11.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 11.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 11.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 11.7.1.1. UK
- 11.7.1.UK and European Union
12. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)
- 12.1. Market Overview
- 12.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
- 12.7.1.Asia Pacific
- 12.7.1.1. China
- 12.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.2. Japan
- 12.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.3. India
- 12.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.4. Australia
- 12.7.1.4.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.4.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.4.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.4.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.4.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.5. South Korea
- 12.7.1.5.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.5.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.5.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.5.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.5.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.6. Rest of Asia Pacific
- 12.7.1.6.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 12.7.1.6.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 12.7.1.6.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 12.7.1.6.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 12.7.1.6.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 12.7.1.1. China
- 12.7.1.Asia Pacific
13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)
- 13.1. Market Overview
- 13.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 13.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 13.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 13.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 13.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 13.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
- 13.7.1.Latin America
- 13.7.1.1. Brazil
- 13.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 13.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 13.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 13.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 13.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 13.7.1.2. Mexico
- 13.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 13.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 13.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 13.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 13.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 13.7.1.3. Rest of Latin America
- 13.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 13.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 13.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 13.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 13.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 13.7.1.1. Brazil
- 13.7.1.Latin America
14. Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market, 2021-2031, USD (Million)
- 14.1. Market Overview
- 14.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 14.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 14.4. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 14.5. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 14.6. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 14.7.Viral Vectors and Plasmid DNA Manufacturing Market: By Region, 2021-2031, USD (Million)
- 14.7.1.Middle East and Africa
- 14.7.1.1. GCC
- 14.7.1.1.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 14.7.1.1.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 14.7.1.1.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 14.7.1.1.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 14.7.1.1.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 14.7.1.2. Africa
- 14.7.1.2.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 14.7.1.2.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 14.7.1.2.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 14.7.1.2.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 14.7.1.2.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 14.7.1.3. Rest of Middle East and Africa
- 14.7.1.3.1. Viral Vectors and Plasmid DNA Manufacturing Market: By Vector Type, 2021-2031, USD (Million)
- 14.7.1.3.2. Viral Vectors and Plasmid DNA Manufacturing Market: By Workflow, 2021-2031, USD (Million)
- 14.7.1.3.3. Viral Vectors and Plasmid DNA Manufacturing Market: By Application, 2021-2031, USD (Million)
- 14.7.1.3.4. Viral Vectors and Plasmid DNA Manufacturing Market: By End-use, 2021-2031, USD (Million)
- 14.7.1.3.5. Viral Vectors and Plasmid DNA Manufacturing Market: By Disease, 2021-2031, USD (Million)
- 14.7.1.1. GCC
- 14.7.1.Middle East and Africa
15. Company Profile
- 15.1. Lonza
- 15.1.1. Company Overview
- 15.1.2. Financial Performance
- 15.1.3. Product Portfolio
- 15.1.4. Strategic Initiatives
- 15.2. Catapult
- 15.2.1. Company Overview
- 15.2.2. Financial Performance
- 15.2.3. Product Portfolio
- 15.2.4. Strategic Initiatives
- 15.3. uniQure N.V.
- 15.3.1. Company Overview
- 15.3.2. Financial Performance
- 15.3.3. Product Portfolio
- 15.3.4. Strategic Initiatives
- 15.4. FUJIFILM Diosynth Biotechnologies
- 15.4.1. Company Overview
- 15.4.2. Financial Performance
- 15.4.3. Product Portfolio
- 15.4.4. Strategic Initiatives
- 15.5. Kaneka Eurogentec S.A.
- 15.5.1. Company Overview
- 15.5.2. Financial Performance
- 15.5.3. Product Portfolio
- 15.5.4. Strategic Initiatives
- 15.6. Oxford Biomedica
- 15.6.1. Company Overview
- 15.6.2. Financial Performance
- 15.6.3. Product Portfolio
- 15.6.4. Strategic Initiatives
- 15.7. Spark Therapeutics, Inc.
- 15.7.1. Company Overview
- 15.7.2. Financial Performance
- 15.7.3. Product Portfolio
- 15.7.4. Strategic Initiatives
- 15.8. Cobrabiologics
- 15.8.1. Company Overview
- 15.8.2. Financial Performance
- 15.8.3. Product Portfolio
- 15.8.4. Strategic Initiatives
- 15.9. Merck KGaA
- 15.9.1. Company Overview
- 15.9.2. Financial Performance
- 15.9.3. Product Portfolio
- 15.9.4. Strategic Initiatives
- 15.10. Other Notable Players
- 15.10.1. Company Overview
- 15.10.2. Financial Performance
- 15.10.3. Product Portfolio
- 15.10.4. Strategic Initiatives
List of Tables
- TABLE 1 Global Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 2 Global Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 3 Global Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 4 Global Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 5 Global Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 6 Global Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 7 Global Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 8 North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 9 North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 10 North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 11 North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 12 North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 13 North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 14 North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 15 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 16 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 17 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 18 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 20 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 21 U.S. Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 22 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 23 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 24 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 25 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 26 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 27 Canada Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 28 Canada Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 29 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 30 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 31 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 32 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 33 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 34 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 35 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 36 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 37 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 38 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 39 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 40 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 41 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 42 UK and European Union Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 43 UK Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 44 UK Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 45 UK Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 46 UK Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 47 UK Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 48 UK Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 49 UK Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 50 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 51 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 52 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 53 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 54 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 55 Germany Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 56 Germany Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 57 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 58 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 59 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 60 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 61 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 62 Spain Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 63 Spain Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 64 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 65 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 66 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 67 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 68 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 69 Italy Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 70 Italy Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 71 France Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 72 France Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 73 France Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 74 France Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 75 France Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 76 France Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 77 France Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 78 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 79 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 80 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 81 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 82 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 83 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 84 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 85 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 86 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 87 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 88 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 89 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 90 Asia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 91 Asia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 92 China Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 93 China Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 94 China Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 95 China Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 96 China Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 97 China Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 98 China Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 99 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 100 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 101 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 102 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 103 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 104 Japan Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 105 Japan Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 106 India Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 107 India Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 108 India Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 109 India Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 110 India Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 111 India Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 112 India Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 113 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 114 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 115 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 116 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 117 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 118 Australia Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 119 Australia Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 120 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 121 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 122 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 123 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 124 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 126 South Korea Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 127 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 128 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 134 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 135 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 136 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 137 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 138 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 139 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 140 Brazil Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 141 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 143 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 144 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 145 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 146 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 147 Mexico Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 148 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 149 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 150 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 151 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 152 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 153 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 154 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 155 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 156 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 157 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 158 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 159 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 160 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 161 Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 162 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 163 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 164 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 165 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 166 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 167 GCC Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 168 GCC Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 169 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 170 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 171 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 172 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 173 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 174 Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 175 Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
- TABLE 176 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, 2021-2031, USD (Million)
- TABLE 177 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Workflow, 2021-2031, USD (Million)
- TABLE 178 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Upstream Manufacturing, 2021-2031, USD (Million)
TABLE 179 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Downstream Manufacturing, 2021-2031, USD (Million)
TABLE 180 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Application, 2021-2031, USD (Million)
- TABLE 181 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By End-use, 2021-2031, USD (Million)
- TABLE 182 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market By Disease, 2021-2031, USD (Million)
List of Figures
- FIG. 1 Global Viral Vectors and Plasmid DNA Manufacturing Market: Market Coverage
- FIG. 2 Research Methodology and Data Sources
- FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
- FIG. 4 Global Viral Vectors and Plasmid DNA Manufacturing Market: Quality Assurance
- FIG. 5 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022
- FIG. 6 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022
- FIG. 7 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022
- FIG. 8 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022
- FIG. 9 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022
- FIG. 10 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Geography, 2022
- FIG. 11 Market Geographical Opportunity Matrix - Global Viral Vectors and Plasmid DNA Manufacturing Market, 2022
FIG. 12Market Positioning of Key Viral Vectors and Plasmid DNA Manufacturing Market Players, 2022
FIG. 13Global Viral Vectors and Plasmid DNA Manufacturing Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
- FIG. 14 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type, 2022 Vs 2031, %
- FIG. 15 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Workflow, 2022 Vs 2031, %
- FIG. 16 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Application, 2022 Vs 2031, %
- FIG. 17 Global Viral Vectors and Plasmid DNA Manufacturing Market, By End-use, 2022 Vs 2031, %
- FIG. 18 Global Viral Vectors and Plasmid DNA Manufacturing Market, By Disease, 2022 Vs 2031, %
- FIG. 19 U.S. Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 20 Canada Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 21 Rest of North America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 22 UK Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 23 Germany Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 24 Spain Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 25 Italy Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 26 France Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 27 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 28 China Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 29 Japan Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 30 India Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 31 Australia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 32 South Korea Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 33 Rest of Asia Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 34 Brazil Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 35 Mexico Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 36 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 37 GCC Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 38 Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
- FIG. 39 Rest of Middle East and Africa Viral Vectors and Plasmid DNA Manufacturing Market (US$ Million), 2021 - 2031
